CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has greatly improved
the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend …

Cytotoxic CD8+ T cells play a key role in the elimination of intracellular infections and
malignant cells and can provide long-term protective immunity. In the response to infection …

Adaptive immune responses mediated by T cells and B cells are crucial for protective
immunity against pathogens and tumors. Differentiation and function of immune cells require …

Cancer progression often benefits from the selective conditions present in the tumour
microenvironment, such as the presence of cancer-associated fibroblasts (CAFs) …

Studies have reported a positive correlation between elevated CD8+ T cells in the tumor
microenvironment (TME) and good prognosis in cancer. However, the mechanisms linking T …

Despite great success in cancer immunotherapy, immune checkpoint-targeting drugs are not
the most popular weapon in the armory of cancer therapy. Accumulating evidence suggests …

Adoptive T cell therapy (ACT) produces durable responses in some cancer patients;
however, most tumors are refractory to ACT and the molecular mechanisms underlying …

T cell dysfunction in solid tumors results from multiple mechanisms. Altered signaling
pathways in tumor cells help produce a suppressive tumor microenvironment enriched for …

Determining mechanisms of resistance to αPD-1/PD-L1 immune-checkpoint immunotherapy
is key to developing new treatment strategies. Cancer-associated fibroblasts (CAF) have …